Results 201 to 210 of about 36,129 (239)
Some of the next articles are maybe not open access.

Adalimumab

Nature Reviews Drug Discovery, 2003
Melanie Brazil
exaly   +3 more sources

Adalimumab

BioDrugs, 2007
Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). The clinical efficacy and safety of adalimumab in patients with moderate to severe Crohn's disease has been demonstrated in four pivotal, randomized, double-blind trials (CLASSIC-I, GAIN, CHARM, and CLASSIC-II) that ...
Greg L, Plosker   +1 more
openaire   +3 more sources

Adalimumab

American Journal of Clinical Dermatology, 2009
Adalimumab is a recombinant, human, IgG1 monoclonal antibody specific for tumor necrosis factor. The clinical efficacy and safety of adalimumab (40 mg administered subcutaneously every other week) in patients with moderate-to-severe chronic plaque psoriasis have been demonstrated in several randomized, double-blind clinical trials, including the ...
Katherine F, Croom, Paul L, McCormack
openaire   +2 more sources

Adalimumab

Drugs, 2006
Adalimumab, a fully human monoclonal antibody, is a tumour necrosis factor antagonist that has been investigated for efficacy in psoriatic arthritis, based on well-established use of the drug in rheumatoid arthritis. In well-controlled Phase III trials, adalimumab (40 mg administered subcutaneously every other week) has shown efficacy in adult patients
Dene, Simpson, Lesley J, Scott
openaire   +2 more sources

Adalimumab

Annales de Dermatologie et de Vénéréologie, 2011
F, Aubin, H, Barthelemy
  +7 more sources

Home - About - Disclaimer - Privacy